Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Monitoring Guidelines for Conventional Synthetic DMARDs
Description
The presentation discusses monitoring guidelines for conventional synthetic DMARDs, particularly focusing on methotrexate, azathioprine, and mycophenolate. Methotrexate, an older medication, poses risks such as myelosuppression, liver toxicity, and increased infection risk, necessitating careful monitoring at baseline and during treatment. Baseline tests include CBC, liver and kidney functions, hepatitis screening, and TB screening, with frequent monitoring recommended in the first few months. Specific cases are explored to illustrate monitoring nuances, especially regarding dose adjustments based on patient risk factors such as kidney function and liver enzyme levels. Azathioprine metabolism is unique and checking TPMT levels before initiation is crucial to evaluate myelosuppression risk. Monitoring of metabolite levels during treatment helps assess compliance and adjust dosages as necessary. Mycophenolate similarly requires monitoring for hematological side effects and drug interactions. Overall, the presentation underscores the importance of monitoring to manage potential serious side effects associated with these medications while optimizing their clinical efficacy.
View moreConclusions
- Conventional synthetic DMARDs like methotrexate, azathioprine, and mycophenolate require careful monitoring due to their potential for serious side effects.
- Methotrexate can cause myelosuppression, liver toxicity, and increased risk of infections, necessitating regular CBC and liver function tests during treatment.
- Patients starting methotrexate with risk factors such as renal impairment should begin on lower doses with increased monitoring frequency.
- If liver function tests are elevated to less than threefold the upper limit of normal, methotrexate can typically be continued with follow-up in a few weeks.
- For patients on methotrexate with cumulative doses exceeding 3.5-4 grams or 1.5-2 grams depending on risk factors, hepatology referral may be warranted.
- Azathioprine carries risks of myelosuppression and pancreatitis; TPMT testing before initiation helps guide therapy and prevent toxicity.
- Monitoring thiopurine metabolites can assist in optimizing azathioprine dosing and assessing adherence to treatment.
- Mycophenolate may cause gastrointestinal side effects and hematologic abnormalities requiring regular blood monitoring similar to other DMARDs.
- Overall, while these drugs are effective, proper monitoring is essential to manage and mitigate risks of toxicity.
- Menter et al. JAAD. June 2020
- Terrault et al. Hepatology. 2018 67 (4)
- Perrillo et al. Gastroenterology. 2015 148
- Zakerska-Banaszak et al. Toxics. 2022 10 (4)